10 completed. 10 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 10 |
Follow dactolisib: new trials by email Literature Review of dactolisib trials Research Report on dactolisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients BEZ235, BKM120 - Castration-resistant Prostate Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 43 | 2012-09-01 | 2020-12-09 |
| A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia BEZ235 - Acute Lymphoblastic Leukemia, Leukemia, Myelocytic, Acute | Phase 1 | Completed | Goethe University | 24 | 2012-06-01 | 2023-02-16 |
| A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab BEZ235 + Trastuzumab Phase l/Phase ll), Lapatinib + Capecitabine (Phase II) - Locally Advance Breast Cancer (LABC), Metastatic Breast Cancer (MBC) | Phase 1 | Completed | Novartis Pharmaceuticals | 5 | 2012-02-01 | 2020-12-09 |
| Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors RAD001 + BEZ235 - Advanced Solid Tumors, Metastatic Breast Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 46 | 2012-01-01 | 2020-12-21 |
| Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients BEZ235 + MEK162 - Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor | Phase 1 | Completed | Pfizer | 29 | 2011-07-08 | 2020-10-09 |
| Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors BEZ235 - Malignant Solid Tumour | Phase 1 | Completed | SCRI Development Innovations, LLC | 33 | 2011-04-01 | 2015-05-01 |
| A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab BEZ235 + paclitaxel, BKM120 + paclitaxel, BEZ235 + paclitaxel + trastuzumab - Metastatic or Locally Advanced Solid Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 110 | 2011-01-01 | 2020-12-09 |
| PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer BEZ235, BKM 120, Letrozole - Metastatic Breast Cancer | Phase 1 | Completed | Vanderbilt-Ingram Cancer Center | 72 | 2010-11-01 | 2016-07-25 |
| A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors BEZ235 - Advanced Solid Tumor | Phase 1 | Completed | Novartis Pharmaceuticals | 35 | 2010-10-01 | 2020-12-09 |
| A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer BEZ235 - Breast Cancer, Advanced Solid Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 183 | 2006-12-21 | 2020-12-09 |
Breast Neoplasms (4) · Neoplasm Metastasis (2) · Neoplasms (2) · Breast Diseases (1) · Carcinoma, Renal Cell (1) · Hamartoma Syndrome, Multiple (1) · Leukemia, Myeloid, Acute (1) · Pancreatic Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Triple Negative Breast Neoplasms (1)
Novartis Pharmaceuticals (6) · Goethe University (1) · Pfizer (1) · SCRI Development Innovations, LLC (1) · Vanderbilt-Ingram Cancer Center (1)
Spain (6) · United States (6) · United Kingdom (4) · Belgium (3) · France (3) · Germany (3) · Canada (2) · Netherlands (2) · Australia (1) · Italy (1) · Japan (1) · New Zealand (1) · Switzerland (1)
Ingrid Mayer, MD (1) · Joerg Chromik, Dr. (1) · Johanna C Bendell, M.D. (1)